Premium
Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy
Author(s) -
Miyaki Daisuke,
Aikata Hiroshi,
Kan Hiromi,
Fujino Hatsue,
Urabe Ayako,
Masaki Keiichi,
Fukuhara Takayuki,
Kobayashi Tomoki,
Naeshiro Noriaki,
Nakahara Takashi,
Kawaoka Tomokazu,
Hiramatsu Akira,
Takahashi Shoichi,
Ishikawa Masaki,
Kakizawa Hideaki,
Awai Kazuo,
Chayama Kazuaki
Publication year - 2013
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12311
Subject(s) - sorafenib , medicine , hepatocellular carcinoma , refractory (planetary science) , gastroenterology , oncology , survival rate , chemotherapy , physics , astrobiology
Background and Aim It has been reported about poor prognosis in patients with advanced hepatocellular carcinoma ( HCC ) refractory to hepatic arterial infusion chemotherapy ( HAIC ). We assessed the survival benefits of sorafenib therapy for advanced HCC in HAIC refractory patients. Methods The study subjects were 191 patients with advanced HCC who had been treated with HAIC . Sorafenib was used in 27 patients who finally failed to respond to HAIC ( HAIC /sorafenib group). Clinical outcome was compared between HAIC /sorafenib and HAIC alone groups. Results There were no significant differences in clinical characteristics and response rate of HAIC between the two groups (response rate: 25.9%, HAIC /sorafenib group; 30.4%, HAIC alone group). The median survival time ( MST ) for all patients was 11.0 months. The survival rate was significantly higher in the HAIC /sorafenib group than HAIC alone group ( MST 22.2 vs 8.7 months, P = 0.017). From administration sorafenib, the disease control rate was 51.8% with MST of 10.4 months. Among HAIC non‐responders, the survival rate was significantly higher in the HAIC /sorafenib group than HAIC alone group. Multivariate analysis identified additional therapy with sorafenib as significant and independent determinant of overall survival in all patients and HAIC non‐responders. Conclusion Additional therapy with sorafenib could probably improve the prognosis of HAIC refractory patients.